Photocure ASA · OSL:PHO
Photocure ASA — Jefferies 2012 Global Healthcare Conference
20 slides from Photocure ASA's conference presentation, Nov 14, 2012
Slide 1: Photocure ASA Executing the Strategy
Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO
Slide 2: Disclaimer
Disclaimer The information included in this Presentation contains certain forward-looking statements that address activities, events or developments that Photocure ASA (“the Company”) expects, projects, believes or anticipates will or may occur in the future. These statements are based on various as
Slide 3: Business Strategy
Business Strategy • Objectives: – Build a specialty pharma company – Maximise potential of innovative Photodynamic Technology Platform • Strategy: – Leverage proven experience to develop, register and commercialize new products in cancer and dermatology – Partner with Industry leaders to accelerate
Slide 4: Photocure's Advantage
Photocure’s Advantage Experts in Photodynamic Technologies Strong IP portfolio Track record of success in bringing PDT products to the market Innovative and proven – multiple applications Few / limited side effects 4
Slide 5: Commercial Operations
Commercial Operations
Slide 6: Hexvix/Cysview Improved Detection of Bladder Cancer
Hexvix/Cysview Improved Detection of Bladder Cancer • Detects more patients (+30%) with Bladder Cancer and detects more lesions • Improves the tumor resection • Reduces tumor recurrence • A significant advance for patient management • Well documented with more than 100 peer reviewed publications Cys
Slide 7: Global Hexvix/Cysview Strategy
Global Hexvix/Cysview Strategy • Continued execution on our strategy to build Photocure into a specialty pharmaceutical company by: – Strategic collaboration with Ipsen • Ipsen territory is worldwide, ex US and Nordics – Commercializing directly in the US market • Photocure is directly marketing and
Slide 8: Ipsen – a Strong, Strategic Partner
Hexvix Ipsen – a Strong, Strategic Partner • Global, specialty-driven pharmaceutical company focused on four franchises, most importantly Uro-Oncology – Sales >€1.1B in 2011 • Strong and well established Uro-Oncology Franchise, led by Decapeptyl® – Decapeptyl sales > €280M in 2011 – Marketed in over
Slide 9: Cysview Critical Success Factors in the US
Cysview Critical Success Factors in the US • Drive installed base of blue light scopes – Further enhance strong collaboration with Karl Storz Americas • Building awareness through institutional PR – Upgraded cystoscope approved in May significantly expands market access • Plan in place to expand sco
Slide 10: Pipeline
Pipeline
Slide 11: Creating Value Diverse Product Portfolio
Creating Value Diverse Product Portfolio Technology Indication Phase 1 Phase 2 Phase 3 Status • Phase 2b results to be reported in 4Q 2012 Treatment of • Commercialization through Cevira® PDT precursors of partners cervical cancer • Significant interest from potential partners • Formulation prototyp
Slide 12: High Unmet Need in Acne
High Unmet Need in Acne • High unmet need in the segment of moderate to severe acne Sales, Billions – Current mainstay of therapy are oral, systemic antibiotics, 0,25 Topicals retinoids, combinations 0,35 Isotretinoin – Value of this segment ~USD 900 million globally 0,3 Oral Antibiotics Other Orals
Slide 13: Visonac Summary of Clinical Trial Results
Visonac® Summary of Clinical Trial Results • Visonac phase 2b results demonstrated significant efficacy versus control – Statistically significant reduction in inflammatory lesions (primary end point) – Statistically significant higher treatment success rate as defined by reduction in acne severity
Slide 14: Cevira: Cancers induced by HPV
Cevira Cancers induced by HPV • Cervical HPV infection highly prevalent and growing – 80% of all women have HPV infections during their lifetime – Represents 4-5 million women in US alone – At least 10% may become CIN 2/3 – May lead to cervical cancer without intervention • Potential alternative to
Slide 15: Cevira Phase 2b Trial results in 4Q
Cevira Phase 2b Trial results in 4Q • Phase 2b study with integrated drug- delivery device started in June 2011 • Enrollment completed – 262 patients at 23 centers in Europe and the US • Primary endpoint: complete or partial response 3 months after treatment (histology, cytology and HPV) – Results e
Slide 16: Lumacan Detection of Colorectal Cancer
Lumacan Detection of Colorectal Cancer • Lumacan: Photodynamic colorectal diagnosis Colorectal Cancer 3rd most commonly diagnosed and 2nd most deadly cancer worldwide. 500,000 new cases each year in the US and EU Lumacan increases detection rate for colon cancer, as an adjunct to white light col
Slide 17: Financials
Financials
Slide 18: Profit & Loss Third quarter 2012
Profit & Loss Third quarter 2012 MNOK Cancer Derm Q3 '12 Q3 '11 YTD '12 YTD '11 Sales revenues 18.1 2.8 20.9 17.4 58.3 51.9 Signing fee and milestones 0.0 2.9 2.9 14.9 31.1 20.6 Total revenues 18.1 5.6 23.8 32.3 89.5 72.5 Gross profit 15.1 5.5 20.5 30.4 81.4 64.1 Operating profit/loss(-) -19.2 -8.2
Slide 19: Summary and Outlook
Summary and Outlook
Slide 20: Key Milestones 2012
Key Milestones 2012 2012 Year to Date 2012 4 Q 2012 Highlights Focus Successfully launched Cysview in US Results from Cevira Phase 2b clinical Continued to drive adoption of Allumera trial available in US Drive growth of Cysview in the US Ipsen secured strong start with Hexvix Work close
Photocure — Jefferies 2012 Global Healthcare Conference on 6ix